Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series
Regina Berkovich, Jonathan Calkwood, Heidi Crayton, April Erwin, Simon Faissner, Ralf Gold, Joshua Katz, Mark Leekoff
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsChronic Lymphocytic Leukemia Research · Monoclonal and Polyclonal Antibodies Research · HER2/EGFR in Cancer Research
In the published article, there was an error in affiliation 1. Instead of “Berkovich MS Center and Research Institute, West Hollywood, CA, United States,” it should be “Regina Berkovich MD, PhD Inc (MS Center and Research Institute), West Hollywood, CA, United States.”
Also, there was an error in Figure 1, Figure 3, and Figure 4 as published. The y-axis titles of these figures contained a typo listing the unit of measure as “cells/¼ L”; the correct unit of measure is “cells/µL.” The corrected Figure 1, Figure 3, and Figure 4 and their captions appear below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.